Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
  2. >
  3. Earnings
  4. >
  5. Bristol Myers Squibb Reports Third Quarter 2024 Financial Results
BMY.N

Bristol Myers Squibb Reports Third Quarter 2024 Financial Results

stocks logo
BMY.N
2024-10-312mins
Content

Bristol Myers Squibb Reports Third Quarter 2024 Financial Results

Bristol Myers Squibb (NYSE:BMY) has reported its financial results for the third quarter ending September 30, 2024. The company showcased an 8% increase in revenue, spotlighting its focus on sustainable growth initiatives.

Key Financial Metrics:

Metric Q3 2024 Q3 2023 YoY Change Consensus Estimate
Total Revenue $11.9B N/A +8% $11.28B
GAAP EPS $0.60 $0.93 -35.5% N/A
Non-GAAP EPS $1.80 $2.00 -10% $1.49

Interpretation: Bristol Myers Squibb exceeded revenue expectations, reporting $11.9 billion versus the $11.28 billion consensus estimate. However, both GAAP and Non-GAAP earnings per share saw a year-over-year decline due to increased research and development expenses and the impact of licensing income.

Revenue Performance by Segment:

Segment Q3 2024 Revenue YoY Change
Growth Portfolio $5.8B +18%
Legacy Portfolio $6.1B +1%

Interpretation: The Growth Portfolio led the company's performance with an 18% year-over-year increase, driven by strong demand for Reblozyl, Breyanzi, Camzyos, and Opdualag. The Legacy Portfolio saw modest growth, bolstered by demand for Eliquis, counteracted somewhat by Sprycel's generic erosion.

Key Developments and Operational Highlights: - U.S. approval of Cobenfy, a novel treatment for schizophrenia, marking a significant milestone in the company's neuroscience endeavors. - Continual growth in Eliquis sales. - Increase in research and development expenditure due primarily to recent acquisitions.

Comments from Company Officers: Christopher Boerner, Ph.D., board chair and chief executive officer, emphasized the company's strategic focus on its Growth Portfolio, highlighting the approval of Cobenfy as a transformative milestone. He reiterated the commitment to delivering shareholder value through robust execution and patient-driven results.

Forward Guidance: Bristol Myers Squibb raised its 2024 revenue guidance to approximately +5%, anticipating a Non-GAAP EPS range of $0.75 to $0.95.

Stock Price Movement: Following the earnings release, Bristol Myers Squibb experienced a modest stock price increase of approximately 0.30%.

This earnings report underscores Bristol Myers Squibb’s strategic growth trajectory and its efforts to sustain momentum despite market challenges.

For more in-depth analysis and insights, stay tuned with our platform to stay ahead of the market.

Join Intellectia

Share

Heat List
Symbol
Latest Price
% Chg
$
%
$
%
$
%
$
%
$
%
$
%
$
%
$
%
$
%
$
%

Want more financial insights delivered directly to your inbox?

Subscribe now and receive handpicked financial news, insights, and trending topics.

FAQs

arrow icon

arrow icon

arrow icon

arrow icon

arrow icon

AER.N
AerCap Q1 2025: Strong Earnings & Positive Outlook- Intellectia AI™
Intellectia.AI1 months ago
GRMN.N
Garmin Ltd Q1 2025 Earnings: Strong Growth Across Sectors- Intellectia AI™
Intellectia.AI1 months ago
ETSY.O
Etsy Inc Q1 2025 Earnings: Growth Amidst Challenges- Intellectia AI™
Intellectia.AI1 months ago
TW.O
Tradeweb Markets Q1 2025 Earnings: Strong Growth Momentum- Intellectia AI™
Intellectia.AI1 months ago

Share

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free